A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/17 (2006.01) A61K 38/16 (2006.01) A61K 48/00 (2006.01) A61P 1/16 (2006.01) C07K 14/47 (2006.01)
Patent
CA 2447249
The present invention relates to the use of the A20-binding inhibitor of NF- .kappa.B activation (ABIN), or a functional fragment or variant thereof to protect against TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN.
La présente invention concerne l'utilisation de l'inhibiteur de liaison A20 d'activation NF-$(g)kB (ABIN) ou un fragment fonctionnel ou un variant correspondant, en matière de protection contre une insuffisance hépatique induite par TNF, telle qu'une hépatite virale et une maladie du foie liée à l'alcool. Notamment, cette invention a trait à la prévention des effets toxiques desdites maladies, y compris la létalité par surexpression d'ABIN.
Beyaert Rudi
Delaei Filip
Libert Claude
Van Huffel Sofie
Wielockx Ben
Fetherstonhaugh & Co.
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw
LandOfFree
Abin-mediated hepatitis protection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Abin-mediated hepatitis protection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abin-mediated hepatitis protection will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1444734